IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 131 -3.42%
27 May - close price
iolcp.com BSE: 524164 NSE: IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Business Segment
a) Pharmaceuticals Segment [1]
Product Portfolio: Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Paracetamol, Clopidogrel, Pantoprazole Sodium, Fenofibrate, Levetiracetam, Lamotrigine, Losartan Potassium

Website BSE NSE
  • Market Cap ₹ 3,857 Cr.
  • Current Price ₹ 131
  • High / Low ₹ 139 / 67.1
  • Stock P/E 26.4
  • Book Value ₹ 61.3
  • Dividend Yield 0.76 %
  • ROCE 11.2 %
  • ROE 8.38 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 22.1%
  • Promoter holding has increased by 4.86% over last quarter.

Cons

  • Company has a low return on equity of 7.70% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
587 563 545 520 504 502 526 523 528 552 568 580 619
492 491 481 476 454 451 484 476 465 490 510 523 527
Operating Profit 95 73 64 44 50 51 42 47 63 62 57 57 92
OPM % 16% 13% 12% 9% 10% 10% 8% 9% 12% 11% 10% 10% 15%
9 7 7 8 8 7 6 4 5 7 7 -6 2
Interest 5 4 4 4 3 2 4 4 4 4 3 4 3
Depreciation 12 14 16 16 16 17 18 19 19 20 20 20 20
Profit before tax 87 61 51 32 37 40 26 28 45 46 40 28 71
Tax % 26% 25% 26% 28% 26% 24% 26% 26% 30% 25% 26% 25% 25%
65 46 38 23 28 30 19 21 31 34 30 21 53
EPS in Rs 2.21 1.56 1.29 0.79 0.94 1.02 0.65 0.70 1.07 1.16 1.02 0.70 1.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,184 2,217 2,133 2,079 2,319
1,925 1,991 1,902 1,877 2,050
Operating Profit 259 226 231 202 269
OPM % 12% 10% 11% 10% 12%
17 25 30 22 10
Interest 8 16 16 15 15
Depreciation 43 46 63 72 80
Profit before tax 225 189 182 138 184
Tax % 25% 26% 26% 27% 25%
168 139 134 101 138
EPS in Rs 5.71 4.74 4.58 3.44 4.69
Dividend Payout % 14% 17% 22% 23% 21%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 2%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 2%
TTM: 44%
Stock Price CAGR
10 Years: 18%
5 Years: 0%
3 Years: 14%
1 Year: 49%
Return on Equity
10 Years: %
5 Years: 9%
3 Years: 8%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 59 59 59 59 59
Reserves 1,334 1,449 1,553 1,629 1,740
44 80 33 117 135
526 435 600 577 653
Total Liabilities 1,962 2,022 2,244 2,382 2,587
561 752 933 1,171 1,184
CWIP 105 90 101 22 94
Investments 2 20 20 21 21
1,294 1,161 1,190 1,169 1,289
Total Assets 1,962 2,022 2,244 2,382 2,587

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
93 122 290 179 214
-121 -120 -191 -154 -198
-2 -4 -92 46 -29
Net Cash Flow -29 -2 6 70 -13
Free Cash Flow -58 -87 17 -34 43
CFO/OP 60% 75% 144% 97% 94%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 79 83 81 90 95
Inventory Days 95 77 111 95 91
Days Payable 95 74 123 112 118
Cash Conversion Cycle 79 86 69 73 68
Working Capital Days 71 72 71 58 53
ROCE % 14% 12% 9% 11%

Insights

In beta
Mar 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Captive Power Generation Capacity
MW ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Ethyl Acetate Installed Capacity
MTPA ・Standalone data
Ibuprofen Installed Capacity
MTPA ・Standalone data
Global Market Share - Ibuprofen
% ・Standalone data
Iso Butyl Benzene (IBB) Installed Capacity
MTPA ・Standalone data
Geographic Presence (Countries)
Number ・Standalone data
Metformin HCL Installed Capacity
MTPA ・Standalone data
Number of EU-CEP Approvals
Number ・Standalone data
Paracetamol Installed Capacity
MTPA ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

5 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62% 52.62% 52.62% 57.48%
3.54% 2.33% 2.18% 1.40% 1.39% 1.63% 1.49% 1.47% 2.59% 2.25% 2.08% 1.72%
0.25% 0.35% 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02% 0.05% 0.03% 0.02%
48.02% 49.12% 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76% 45.10% 45.26% 40.78%
No. of Shareholders 1,26,0041,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,550

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls